Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma
(HCC). Alternative first-and second-line treatments are a significant unmet medical need …

Sorafenib is a specific adenosine triphosphate–competitive RAF inhibitor used as a first‐line
treatment of advanced hepatocellular carcinoma (HCC). However, the responses are …

Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Because of its heterogeneity, lack of prognostic markers, tumor-escape mechanisms, and
frequent relapse upon surgical intervention, treatment of hepatocellular carcinoma (HCC) …

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …